Immunotherapy in Bladder Cancer - Arjun Balar
November 7, 2018
(Length of Discussion: 16 min)
Arjun Balar and Alicia Morgans discuss outcomes in bladder cancer trials with a focus on primary endpoints, duration of response, and adverse events. Trials to practice with accurate clinical staging may lead to the ultimate goal of organ conservation in this patient population.
Biographies:
Arjun Balar, MD is the director of the genitourinary medical oncology program at NYU Langone’s Perlmutter Cancer Center.
Alicia Morgans, MD, MPH
Arjun Balar and Alicia Morgans discuss outcomes in bladder cancer trials with a focus on primary endpoints, duration of response, and adverse events. Trials to practice with accurate clinical staging may lead to the ultimate goal of organ conservation in this patient population.
Biographies:
Arjun Balar, MD is the director of the genitourinary medical oncology program at NYU Langone’s Perlmutter Cancer Center.
Alicia Morgans, MD, MPH
Related Content:
Pembrolizumab for High-Risk Non–Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to BCG: Phase 2 Keynote-057 Trial
Invited Discussant - Pembrolizumab for High-Risk Non–Muscle Invasive Bladder Cancer Unresponsive to BCG: Phase 2 Keynote-057 Trial
Nivolumab Alone or in Combination with Ipilimumab in Patients with Platinum-Pretreated Metastatic Urothelial Carcinoma, including the Expansion from CheckMate 032
FDA Approves Immunotherapy Pembrolizumab to Treat Patients with BCG-Unresponsive, High-Risk, Non-Muscle Invasive Bladder Cancer